A Study to Evaluate ART101 in Adult Participants With Hypertension
Status:
TERMINATED
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
This is a Phase 1, first-in-human, randomized, double-blind, placebo-controlled, study to assess the safety, tolerability, Pharmacokinetics (PK), and pharmacodynamics (PD) of a single dose of ART101 administered via subcutaneous injection to hypertensive adult participants. An anticipated 5 dose cohorts (one as optional) with maximum of 40 participants will be randomized in SAD study.